REGENXBIO, Inc.

A Multi-Billion Dollar Gene Therapy Pipeline

About this Event

Regenxbio [NASDAQ: RGNX] is an advanced gene therapy company with three assets in pivotal trials. Each is set to reach critical milestones in the next 12 months, creating large commercial opportunities in Wet AMD, Diabetic Retinopathy, and Duchenne Muscular Dystrophy.

Regenxbio is one of a few gene therapy companies worldwide with a cGMP facility capable of producing their drugs at commercial scale. They already have partnerships with global pharmaceutical companies including Abbvie, Nippon Shinyaku, and Novartis.

Please watch our Fireside Chat with Regenxbio Chief Commercial Officer, Dr. Ram Palanki, for details of their regenerative treatments and their potential to become standard of care in markets worth a total of $26B.

Video On Demand

– Recorded

December 10

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.